Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1481
Abstract: Pyruvate kinase (PK) deficiency is a rare, hereditary, hemolytic anemia caused by mutations in the PKLR gene encoding the PK enzyme. Mitapivat (previously designated AG‐348) is a first‐in‐class, oral, allosteric activator of PK. We report… read more here.
Keywords: relative bioavailability; food; mitapivat; bioavailability studies ... See more keywords
Long-term mitapivat treatment improves inflammatory pro-fibrotic cardiomyopathy in a murine model of β-thalassemia.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-727
Abstract: Hypertrophic cardiomyopathy (HC) is a severe invalidating complication of ß–thalassemia (ß–thal), contributing to reduced patients' life expectancy. Recently we showed that 12-months old male ß-thal mice develop HC independently from heart iron accumulation, and that… read more here.
Keywords: mice; mitapivat; pro fibrotic; heart ... See more keywords